Analyst Sean Lee CFA of H.C. Wainwright maintained a Buy rating on Monopar Therapeutics Inc (MNPR – Research Report), retaining the price target of $40.00.
Sean Lee CFA has given his Buy rating due to a combination of factors related to Monopar Therapeutics Inc’s strategic advancements and financial outlook. A key driver for this positive outlook is the anticipated submission of the ALXN1840 New Drug Application (NDA) to the FDA for the treatment of Wilson’s disease, expected in early 2026. This potential milestone could open up a significant market opportunity, with an estimated addressable market of $420 million in the U.S. alone, given the prevalence of the disease.
Additionally, Monopar’s ongoing development of MNPR-101, particularly the initiation of a Phase 1 study for its antibody-drug conjugate targeting advanced solid tumors, adds to the company’s growth prospects. The financial assessment, which includes a risk-adjusted net present value analysis and a strong cash position, supports the Buy rating with a 12-month price target of $40.00 per share. However, the rating also considers potential risks such as clinical, regulatory, commercial, financial, and intellectual property challenges.
In another report released on March 19, Piper Sandler also initiated coverage with a Buy rating on the stock with a $76.00 price target.